GlaxoSmithKline has filed a lawsuit in a United States court against Dr Reddy's Laboratories alleging infringement of patent rights of a generic version of 'Imitrex' drug, used for the treatment of migraine.
The entire world is taking up the habit of 'namaste', Modi said.
'There is no shortage of any APIs (active pharmaceutical ingredients) in the country'
The guidelines lay down the processes and premises redesigning, including proper placement of equipments. Yoga institutes and gymnasiums have been asked to plan the floor area based on four metres squared per person.
The state govt has raised drug procurement budget.
Unless you are a fresher, you should not circulate a generic CV for all openings, says Achin Bhattacharyya.
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
Spending allocation covers salaries, consultancy, litigation, material expense and regulatory costs.
Practice these seven easy habits and you'll be amazed at the results, says Aditya Prasad, chief evangelist at Perfios.com.
The worry is that India's cavalier approach to intellectual property may catch on in other parts of the developing world
All of Ranbaxy's India-based factories are currently banned by the FDA from exporting medicines to the United States, the company's largest market, after the regulator's inspection found violation of its so-called good manufacturing practices.
The drug Glivec was a genuinely new and important discovery deserving of patent protection.
A random check had found that tests failed to prove the medicines were same as the patented drugs.\n
Companies known for spending huge amounts on innovation globally have minuscule budgets for India. What's holding them back?
Prime Minister Narendra Modi had asked exporters to prepare a strategy for the next five years and start working in that direction.
Industry must take strong collective action to protect the reputation it enjoys in global markets, says Kiran Mazumdar Shaw.
Indian companies may be able to make generic copies of Roche's anti-influenza drug Tamiflu with its patent still pending in the country.
Firm pleads guilty to lying to US FDA; says it had set aside the money.
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
Increased price control over branded generic medicines has affected its profitability
The vaccine would be first made available to the vulnerable population and eventually, it would be available in the private market for all.
Dhoom 3 boasts of more noise, more bikes and a whole lot of scowling from Aamir Khan.
Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically.
Novartis' threat that it would not introduce new medicines in India after the verdict is hollow, says Anand Grover.
The company had stopped production of generic version of cholesterol lowering drug Lipitor last year as it investigated the issue of potential glass particles in certain lots of the drug.
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the apex court said on Monday that the drug failed to qualify for a patent according to Indian law.
If it gets the USFDA nod, the sales would help to pull the company out of the red.
Take the rediff business quiz and see how much you know about India's pharmaceutical industry.
Companies run till now by mostly their promoters are increasingly inducting professionals to head their teams.
Expectations of Healthcare sector from Union Budget 2013-14.
Prodded by patent cliff & increasing competition, it files application for foray into injectible oncology segment.
India's Orchid Chemicals & Pharmaceuticals Ltd said on Monday that US-based Apotex Corporation would sell its generic cephalosporins and other injectible antibiotics in the United States.\n\n\n\n
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances